MALVERN, Pa. July 16, 2024’ Annovis Bio Inc. (NYSE: ANVS), a prominent late-stage clinical drug platform company, has recently achieved significant milestones in the development of therapies for neurodegenerative disorders, particularly Alzheimer’s Disease (AD) and Parkinson’s Disease (PD). These developments highlight the company’s continuing commitment to pioneering transformative treatments in a highly critical segment of medical science.
FDA Approval for New Crystal Form of Buntanetap’
Annovis Bio announced that the U.S. Food and Drug Administration (FDA) has given its approval to transition to a novel solid form of its leading drug candidate, buntanetap. This decision is expected to have a profound impact on future clinical trials, potentially enhancing the efficacy and stability of the drug. The transition to this new crystalline formulation aims to improve the pharmacokinetics and manufacturability, providing a more consistent therapeutic benefit for patients suffering from neurodegenerative diseases.
Patent Filing for Novel Composition’
In conjunction with the FDA’s approval, Annovis Bio also announced the filing of a new composition of matter patent with the U.S. Patent and Trademark Office. This patent covers unique solid forms of buntanetap and is a strategic move to secure intellectual property rights, building upon a provisional patent filed in June 2023. The company’s scientists have identified and selected the most promising crystal form of buntanetap, which is expected to offer superior therapeutic properties compared to previous formulations.
Investor Webcast and Future Directions’
To keep the investment community informed, Annovis Bio has scheduled an investor webcast to discuss these recent advancements along with future plans for buntanetap. This webcast is particularly significant as it will provide detailed insights into the clinical data for Parkinson’s Disease, highlighting how the transition to the new crystal form and the recent patent filing may positively influence clinical outcomes.
Conclusion’
The recent FDA approval and patent filing represent key advancements in Annovis Bio’s mission to develop cutting-edge treatments for neurodegenerative disorders. Through strategic innovations and rigorous clinical trials, the company continues to make substantial progress in addressing the substantial unmet medical needs for conditions like Alzheimer’s Disease and Parkinson’s Disease.
The forthcoming investor webcast will further elucidate these milestones, providing an opportunity for stakeholders to gain a deeper understanding of Annovis Bio’s journey and its potential impact on neurodegenerative disease therapeutics.
Comments